EGFR and neoplasm: Given that 11q13 amplification has been associated with poor prognosis in HNSCC patients, and, in particular, these three genes have been involved in tumor progression and resistance to radio-, chemotherapy [11,22,23,24,25,26], and EGFR-targeted therapies [27], the herein found distinctive molecular alterations presumably could contribute to the clinical and biological differences between these two different HNSCC subtypes and explain the better prognosis and response to radiotherapy and chemotherapy associated to HPV-positive tumors.